These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30427250)

  • 1. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
    Ogata A; Kato Y; Higa S; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Song SN; Yoshizaki K
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
    Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
    Kondo N; Fujisawa J; Endo N
    Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
    Smolen JS; Avila JC; Aletaha D
    Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Navarro G; Taroumian S; Barroso N; Duan L; Furst D
    Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
    Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
    Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
    Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 20. Tocilizumab in the treatment of rheumatoid arthritis and beyond.
    Shetty A; Hanson R; Korsten P; Shawagfeh M; Arami S; Volkov S; Vila O; Swedler W; Shunaigat AN; Smadi S; Sawaqed R; Perkins D; Shahrara S; Sweiss NJ
    Drug Des Devel Ther; 2014; 8():349-64. PubMed ID: 24729685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.